Fingolimod Hydrochloride

"Fingolimod Hydrochloride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A sphingosine-derivative and IMMUNOSUPPRESSIVE AGENT that blocks the migration and homing of LYMPHOCYTES to the CENTRAL NERVOUS SYSTEM through its action on SPHINGOSINE 1-PHOSPHATE RECEPTORS. It is used in the treatment of MULTIPLE SCLEROSIS.

Descriptor ID	D000068876
MeSH Number(s)	D02.033.100.700.350 D02.033.455.706.431 D02.092.063.700.350
Concept/Terms	Fingolimod Hydrochloride Fingolimod Hydrochloride Hydrochloride, Fingolimod 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride FTY-720 FTY-720 FTY 720 FTY720 Gilenya Gilenya Gilenia Fingolimod Fingolimod

Below are MeSH descriptors whose meaning is more general than "Fingolimod Hydrochloride".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Alcohols [D02.033]
Amino Alcohols [D02.033.100]
Sphingosine [D02.033.100.700]
Fingolimod Hydrochloride [D02.033.100.700.350]
Glycols [D02.033.455]
Propylene Glycols [D02.033.455.706]
Fingolimod Hydrochloride [D02.033.455.706.431]
Amines [D02.092]
Amino Alcohols [D02.092.063]
Sphingosine [D02.092.063.700]
Fingolimod Hydrochloride [D02.092.063.700.350]

Below are MeSH descriptors whose meaning is related to "Fingolimod Hydrochloride".

Below are MeSH descriptors whose meaning is more specific than "Fingolimod Hydrochloride".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Fingolimod Hydrochloride" by people in this website by year, and whether "Fingolimod Hydrochloride" was a major or minor topic of these publications.

Bar chart showing 15 publications over 8 distinct years, with a maximum of 3 publications in 2006 and 2012

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2006	0	3	3
2009	0	1	1
2012	0	3	3
2013	0	2	2
2015	1	1	2
2016	1	0	1
2017	0	1	1
2019	1	1	2

Below are the most recent publications written about "Fingolimod Hydrochloride" by people in Profiles.

Dasgupta S, Ray SK. Ceramide and Sphingosine Regulation of Myelinogenesis: Targeting Serine Palmitoyltransferase Using microRNA in Multiple Sclerosis. Int J Mol Sci. 2019 Oct 11; 20(20).

View in: PubMed
De Palma RM, Parnham SR, Li Y, Oaks JJ, Peterson YK, Szulc ZM, Roth BM, Xing Y, Ogretmen B. The NMR-based characterization of the FTY720-SET complex reveals an alternative mechanism for the attenuation of the inhibitory SET-PP2A interaction. FASEB J. 2019 06; 33(6):7647-7666.

View in: PubMed
Miller LG, Young JA, Ray SK, Wang G, Purohit S, Banik NL, Dasgupta S. Sphingosine Toxicity in EAE and MS: Evidence for Ceramide Generation via Serine-Palmitoyltransferase Activation. Neurochem Res. 2017 Oct; 42(10):2755-2768.

View in: PubMed
Becker-Krail D, Farrand AQ, Boger HA, Lavin A. Effects of fingolimod administration in a genetic model of cognitive deficits. J Neurosci Res. 2017 05; 95(5):1174-1181.

View in: PubMed
Samuvel DJ, Saxena N, Dhindsa JS, Singh AK, Gill GS, Grobelny DW, Singh I. AKP-11 - A Novel S1P1 Agonist with Favorable Safety Profile Attenuates Experimental Autoimmune Encephalomyelitis in Rat Model of Multiple Sclerosis. PLoS One. 2015; 10(10):e0141781.

View in: PubMed
Yu H, Herbert BA, Valerio M, Yarborough L, Hsu LC, Argraves KM. FTY720 inhibited proinflammatory cytokine release and osteoclastogenesis induced by Aggregatibacter actinomycetemcomitans. Lipids Health Dis. 2015 Jul 04; 14:66.

View in: PubMed
Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti D. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest. 2013 Oct; 123(10):4144-57.

View in: PubMed
Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G, Eisfeld AK, Van Brocklyn JR, Briesewitz R, Saddoughi SA, Nagata K, Bittman R, Caligiuri MA, Abdel-Wahab O, Levine R, Arlinghaus RB, Quintas-Cardama A, Goldman JM, Apperley J, Reid A, Milojkovic D, Ziolo MT, Marcucci G, Ogretmen B, Neviani P, Perrotti D. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood. 2013 Sep 12; 122(11):1923-34.

View in: PubMed
Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J, Bielawski J, Szulc ZM, Thomas RJ, Selvam SP, Senkal CE, Garrett-Mayer E, De Palma RM, Fedarovich D, Liu A, Habib AA, Stahelin RV, Perrotti D, Ogretmen B. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med. 2013 01; 5(1):105-21.

View in: PubMed
Podbielska M, Krotkiewski H, Hogan EL. Signaling and regulatory functions of bioactive sphingolipids as therapeutic targets in multiple sclerosis. Neurochem Res. 2012 Jun; 37(6):1154-69.

View in: PubMed

People

Explore

Similar Concepts

Top Journals